r112

R112 是 ATP 竞争性的 Syk 激酶抑制剂，它能够抑制 Syk 激酶活性，Ki=6 nM，IC50=226 nM。

DBPR112 是一种口服有效的基于氟嘧啶的 EGFR 抑制剂，对 EGFRWT 和 EGFRL858R/T790M 的 IC50 分别为 15 nM 和 48 nM。DBPR112 可以占据 ATP 结合位点。DBPR112 具有显着的抗肿瘤功效。

SR11237 是一种泛视黄醇 X 受体 (RXR) 激动剂。 SR11237 导致 RXR/RXR 同源二聚体形成并反式激活包含 RXR 反应元件的报告基因。

DBPR112 is a potent EGFR inhibitor (IC50=487 nM) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. DBPR112), DBPR112 not only displayed a potent inhibitory activity against EGFRL858R/T790M double mutations but also exhibited tenfold potency better than the third-generation inhibitor, osimertinib,against EGFR and HER2 exon 20 insertion mutations. Overall, pharmacokinetic improvement through lead-to-candidate optimization yielded fourfold oral AUC better that afatinib along with F = 41.5%, an encouraging safety profile, and significant antitumor efficacy in in vivo xenograft models.

SR11254-CoA (SR11254-coenzyme A) 是辅酶 A 的一种衍生物。

(12aR)-1,12-Bis(diphenylphosphino)-6,7-dihydrodibenzo[e,g][1,4]dioxocine 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T67395。

Berupipam is a dopamine D1 receptor antagonist.

GR-112000 is a peptide-based tachykinin NK2 receptor antagonist.

UR-144, a synthetic cannabinoid, exhibits high affinity for the peripheral cannabinoid receptor (CB2) with a Ki of 1.8 nM, markedly greater than its affinity for the central cannabinoid receptor (CB1), for which it has a Ki of 150 nM. XLR-11 differs from UR-144 by featuring a fluorine atom on the terminal carbon of the alkyl chain and a methyl group on the C2 carbon of the indole. The specific biological activities of XLR-11 remain uncharacterized. It is designed for forensic and research use only.